Lexicon Pharmaceuticals (LXRX) Change in Accured Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Change in Accured Expenses data on file, last reported at -$6.9 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$6.9 million, up 68.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.4 million (down 795.94% YoY), and the FY2025 annual result was -$30.2 million, down 304.19% from the prior year.
• Change in Accured Expenses declined to -$6.9 million in Q1 2026 per LXRX's latest filing, from -$5.6 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $11.1 million in Q2 2025 and troughed at -$21.7 million in Q1 2025.
• A 5-year average of -$928823.5 and a median of -$2.1 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses surged 750.07% in 2022, then tumbled 257.86% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $4.7 million in 2022, then plunged by 156.31% to -$2.7 million in 2023, then jumped by 443.93% to $9.1 million in 2024, then plunged by 161.89% to -$5.6 million in 2025, then fell by 22.13% to -$6.9 million in 2026.
• Business Quant data shows LXRX's Change in Accured Expenses at -$6.9 million in Q1 2026, -$5.6 million in Q4 2025, and -$14.0 million in Q3 2025.